结直肠癌肝转移的经动脉化疗栓塞:DSM-TACE 相比传统 TACE 改善肿瘤反应,一项前瞻性随机单中心试验
该前瞻性随机单中心试验将50例结直肠癌肝转移患者随机分配至碘油TACE或DSM-TACE,31例完成治疗并评估肿瘤反应。DSM-TACE组按RECIST 1.1的肿瘤反应显著优于传统TACE(p=0.047),肿瘤体积缩小也更显著(p=0.006),但两组中位生存期无显著差异(13个月 vs 16个月,p=0.75)。
要点
- 评估CRLM行TACE后疗效时,DSM-TACE组按RECIST 1.1的肿瘤反应显著优于传统TACE(p=0.047)。
- DSM-TACE组肿瘤体积缩小较传统TACE显著(p=0.006)。
- 两组表观扩散系数(ADC)值在基线和研究终点均无显著差异,ADC不能作为监测TACE疗效的生物标志物。
诊断标准与关键数值
- 传统TACE组:部分缓解(PR)23%,疾病稳定(SD)15%,疾病进展(PD)62%。
- DSM-TACE组:部分缓解(PR)22%,疾病稳定(SD)56%,疾病进展(PD)22%(p=0.047)。
- 两组中位表观扩散系数值在基线无显著差异(p=0.26),在研究终点亦无显著差异(p=0.83)。
临床应用与阅片要点
- 作者认为,CRLM患者可能不仅从DSM-TACE的短时栓塞效应中获益,还可能从更好的肿瘤反应中获益。
- 作者指出,表观扩散系数在两组间无显著差异,不能用作监测TACE治疗效果的生物标志物。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To prospectively evaluate the therapy response of third-line TACE with DSM or lipiodol in the treatment of CRLM using MRI.
METHODS: In this prospective, randomized, single-center trial, patients were randomly assigned to receive TACE therapy with either lipiodol or DSM as the embolization agent. Therapy response was evaluated using MRI. Local tumor response was determined according to RECIST 1.1, and survival data was analyzed using the Kaplan-Meier estimator.
RESULTS: Fifty patients (35 male, 15 female) were randomized and included in the survival analysis, whereas 31 patients completed therapy and were considered for evaluation of tumor responses (cTACE: n = 13, DSM-TACE: n = 18). In the cTACE group, PR was observed in 23%, SD in 15%, and PD in 62%. In the DSM-TACE-group, PR was observed in 22% of patients, SD in 56%, and PD in 22% (p = 0.047). In addition, the DSM-TACE group showed statistically significant tumor volume reduction (p = 0.006). Median apparent diffusion coefficient values were not significantly different between both groups at baseline (p = 0.26) and study endpoint (p = 0.83). Median survival in the cTACE group was 13 months (95% confidence interval, range 5-40 months) compared to 16 months (95% confidence interval, range 1-48 months) in the DSM-TACE group, exhibiting no statistically significant difference (p = 0.75).
CONCLUSION: DSM-TACE showed a significant difference reducing tumor volume and in tumor response according to RECIST 1.1 compared to cTACE. Thus, patients with CRLM might not only benefit from short embolization effect of DSM-TACE but also from better tumor responses. Apparent diffusion coefficients were not significantly different between both groups and cannot be used as a biomarker for monitoring for therapeutic effect of TACE.
KEY POINTS: • To our knowledge, this is the first prospective study that directly compared cTACE and DSM-TACE in patients with CRLM. • DSM-TACE showed a significant difference reducing tumor volume (p = 0.006) and in tumor response according to RECIST 1.1 (p = 0.047) compared to cTACE. • Survival analysis showed a median survival of 13 months in the cTACE group compared to 16 months in the DSM-TACE group (p = 0.75).
引用
- Vogl TJ, Marko C, Langenbach MC, et al. Transarterial chemoembolization of colorectal cancer liver metastasis: improved tumor response by DSM-TACE versus conventional TACE, a prospective, randomized, single-center trial. Eur Radiol. 2020. PMID: 32960329. doi:10.1007/s00330-020-07253-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。